BMI View: Pharmaceutical firms in India are reporting improved performance for the quarter
ended December 2013. This is an early indication of a recovery in the Indian pharmaceutical industry,
following the implementation of the Drug Price Control Order in May 2013. W ..."
BMI View: Due to its large population and substantial unmet medical needs, India represents a
market with strong commercial opportunities for pharmaceutical firms. However, we highlight that
the government is impeding the development of its pharmaceutical sector, main ..."
BMI View: Pharmaceutical firms continue to post varying results in India due to the government's introduction of policies targeting the pharmaceutical industry. These include patent disrespect and price containment policies for both generic and patented drugs. We maintain our bea ..."
BMI View: Despite slowing growth in the Indian pharmaceutical market in the first four months of 2013,
top domestic firms continued to see strong double-digit growth in the latest quarter, outperforming
multinational pharmaceutical firms. We maintain that the Indian government' ..."
BMI View: India continues to be a key emerging market for many pharmaceutical firms, primarily due to its large population and a high burden of communicable and non-communicable diseases. However, we note that constant regulatory flip-flops will remain a downside risk for pharmac ..."
The outlook for India's patented drug market is not promising. The primary reason why sales of these products will not grow swiftly is the country's intellectual property (IP) regime, which is well below international standards. It does not recognise incremental improvements and ..."
Following a patchy performance in 2010/11, many observers questioned what the future might hold for the mainly generic Indian pharmaceutical companies, as health funders put downward pressure on generic prices. However, the industry has bounced back to profit, but the question is ..."
GBI Research's new report "Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment" provides in-depth analysis of the trends, issues and challenge ..."